NK News and Press, NantKwest From 12/21/20

NantKwest (NK), up 21% premarket and privately-held ImmunityBio and NantKwest (NK) have entered into an agreement to merge in a stock-for-stock transaction. The combination will create an immunotherapy and cell therapy company focused on oncology and infectious disease. Together, Im...

QUILT 3.032 study completes planned enrollment of BCG unresponsive non-muscle invasive bladder cancer CIS cohort with 59% probability of patients maintaining complete response for at least 12 months Over 85% of patients in this study have avoided a cystectomy to date Break...

Merged entity brings together 11 Phase II / III clinical trials across oncology and infectious disease that use combined immunotherapy platforms Broad late-stage pipeline for solid tumors including bladder, lung, breast, and pancreatic in addition to infectious disease p...

Gainers: Sonoma Pharmaceuticals (SNOA) +114%. NantHealth (NH) +110%. vTv Therapeutics (VTVT) +59%. aTyr Pharma (LIFE) +33%. NantKwest (NK) +22%.Losers: SELLAS Life Sciences (SLS) -33%. Immutep (IMMP) -29%. Salarius Pharmaceuticals (SLRX) -29%. Nabriva Therapeutics (NBRV) -29%. ALX O...

NantKwest (NK) rises 16% premarket after its partner ImmunityBio announced results from the Challenge study evaluating, hAd5 T-Cell COVID-19 vaccine candidate.BARDA-sponsored study shows second-generation hAd5 vaccine candidate in both subcutaneous and oral formulations inhibits SARS-CoV...

vTv Therapeutics VTVT +128% as MacAndrews & Forbes buys 625K shares.Sonoma Pharmaceuticals SNOA +122% on Crown Laboratories partnership.FAT Brands FAT +60% on plan to merge with controlling shareholder Fog Cutter Capital.Lexicon Pharmaceuticals LXRX +38%...

BARDA-sponsored study shows second-generation hAd5 vaccine candidate in both subcutaneous and room temperature oral formulations inhibits SARS-CoV-2 virus replication to undetectable levels and clears infection within days in 100% of vaccinated non-human primates The secon...

Gainers: [[NM]] +26.7%. [[QTT]] +4.4%. [[RMG]] +3.6%. [[DXYN]] +3.6%. [[WES]] +1.9%.Losers: [[YJ]] -4.2%. [[NK]] -3.3%. [[LOMA]] -3%. [[EDIT]] -2.3%. [[TRVG]] -2%. For further details see: EDIT, WES, NM and TRVG among after-hours movers

N-803 Boosts CD34+ Progenitor-Derived NK Cell Expansion and Functionality Adding N-803 to NK Cell Therapy has Potential to Improve Cancer Immunotherapy ImmunityBio, a privately-held immunotherapy company, today announced the publication in Cancer Immunology, Immunoth...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week aheadThe week ahead will see investors once again weigh the brightening prospects for COVID-19 vaccines against a surging pand...